2019
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer
Aggarwal C, Thompson J, Black T, Katz S, Fan R, Yee S, Chien A, Evans T, Bauml J, Alley E, Ciunci C, Berman A, Cohen R, Lieberman D, Majmundar K, Savitch S, Morrissette J, Hwang W, Elenitoba-Johnson K, Langer C, Carpenter E. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer. JAMA Oncology 2019, 5: 173-180. PMID: 30325992, PMCID: PMC6396811, DOI: 10.1001/jamaoncol.2018.4305.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungClinical Decision-MakingDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMiddle AgedMutationPatient SelectionPhenotypePrecision MedicinePredictive Value of TestsPrognosisProspective StudiesConceptsNon-small cell lung cancerTissue next-generation sequencingMetastatic non-small cell lung cancerCell lung cancerTargetable mutationsNext-generation sequencingLung cancerPlasma testingStage IV non-small cell lung cancerAllele fractionNGS testingClinical implicationsPlasma next-generation sequencingPersonalized therapyReal-world clinical settingProspective cohort studyResponse Evaluation CriteriaRoutine clinical managementNumber of patientsSolid Tumors responseDNA next-generation sequencingStable diseaseMutation allele fractionCohort studyPartial response
2017
Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma
Gangadhar T, Savitch S, Yee S, Xu W, Huang A, Harmon S, Lieberman D, Soucier D, Fan R, Black T, Morrissette J, Salathia N, Waters J, Zhang S, Toung J, van Hummelen P, Fan J, Xu X, Amaravadi R, Schuchter L, Karakousis G, Hwang W, Carpenter E. Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma. Pigment Cell & Melanoma Research 2017, 31: 73-81. PMID: 28786531, PMCID: PMC5742050, DOI: 10.1111/pcmr.12623.Peer-Reviewed Original ResearchConceptsCell-free DNAStage III/IV patientsTissue next-generation sequencingAdvanced melanoma patientsMonitoring of patientsPrevious therapyIV patientsAdvanced melanomaMelanoma patientsTumor burdenBlood drawUltra-deep sequencingPatientsPlasma mutationsLiquid biopsyNext-generation sequencingFrequent mutationsAllele fractionTherapyMore mutationsMutationsBiopsyMelanomaBRAF
2016
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Thompson J, Yee S, Troxel A, Savitch S, Fan R, Balli D, Lieberman D, Morrissette J, Evans T, Bauml J, Aggarwal C, Kosteva J, Alley E, Ciunci C, Cohen R, Bagley S, Stonehouse-Lee S, Sherry V, Gilbert E, Langer C, Vachani A, Carpenter E. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clinical Cancer Research 2016, 22: 5772-5782. PMID: 27601595, PMCID: PMC5448134, DOI: 10.1158/1078-0432.ccr-16-1231.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCtDNA next-generation sequencingResistance mutationsNext-generation sequencingTissue sequencingAdvanced non-small cell lung cancerActionable EGFR mutationsCell lung cancerProgressive diseaseConsecutive patientsCtDNA sequencingTargetable driversLung cancerClinical trialsDisease progressionEGFR mutationsUltra-deep sequencingPatient managementExperimental therapiesTumor genotypingCtDNA samplesTissue biopsiesPatientsAccurate diagnosisBlood collection